Insights into the (GCT) Gene/Cell Therapy market & challenges facing market entrants and commercialization | Ascella Health
Continuing advances in cell and gene therapy (CGT) are transforming the pharmacy and point of care ecosystem. Recent launches of new CGTs have yielded mixed results on getting the right therapy to the right patients. The CGTs pipeline and approvals are likely to rise dramatically in the near future. In 2024 alone, up to 21 cell therapy launches and as many as 31 gene therapy launches are on the horizon. Therefore, the launch readiness for these products should be effective so that the therapies can benefit as many patients as possible while ensuring a sufficient return on manufacturers’ investments. With so many new CGTs poised for commercialization, it’s imperative to consider innovative ways for a product launch that benefits CGTs patients. Ensuring that the market, the product, and the company itself are fully prepared for an effective launch will enable success. Podcast Participants: Michelle Rice, CEO, Michelle Rice & Associates Kenneth Mankowski, DO, FACN, MS Neurologist Specialist, CNS & MS Institute Host: Michael Baldzicki
You May Also Like

Israel Today: Ongoing War Report
Israel Today: Ongoing War Report

The Epstein Chronicles
Bobby Capucci

Bloomberg News Now
Bloomberg

Brian Kilmeade Show
FOX News Podcasts

Durham News Today | 2 Min News | The Daily News Now!
The Daily News Now!

The Situation Room with Wolf Blitzer and Pamela Brown
CNN Podcasts

Ranch It Up Radio Show & Podcast
Jeff ”Tigger” Erhardt & Rebecca ”BEC” Wanner, Tigger & BEC

Armstrong & Getty On Demand
iHeartPodcasts

Aristegui Noticias Podcast
Sonoro, Aristegui

The Zone
Sports Radio 810 WHB
Community discussion